about
Immunotherapy targets in pediatric cancer.Identification and Tumour-Binding Properties of a Peptide with High Affinity to the Disialoganglioside GD2.Molecular profiling of childhood cancer: Biomarkers and novel therapiesLipidomics of glycosphingolipids.Experiences of Pediatric Oncology Patients and Their Parents at End of Life: A Systematic Review.Targeting FLT3 Signaling in Childhood Acute Myeloid Leukemia.TNF-α SNP rs1800629 and risk of relapse in childhood acute lymphoblastic leukemia: relation to immunophenotype.
P2860
Q35971029-C04A554F-EB10-44EF-8AC9-E4FC9D98074FQ36157472-3F21AA63-D9B9-4BD8-997C-B7A64594540FQ36250783-87A2F78E-E7D1-4FC7-A8B8-6F4B769389C7Q37512584-9BEFBD48-CA89-4BA9-9D13-2A428E675C86Q38556223-41E2C17B-811C-4A11-AEDB-B01AC198AB86Q47150923-27A67618-F778-4B24-9B52-BC8B618367FAQ52877127-11DCC101-0C11-44C8-8C3D-4CB8669FB100
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Targeted therapy in pediatric and adolescent oncology.
@en
Targeted therapy in pediatric and adolescent oncology.
@nl
type
label
Targeted therapy in pediatric and adolescent oncology.
@en
Targeted therapy in pediatric and adolescent oncology.
@nl
prefLabel
Targeted therapy in pediatric and adolescent oncology.
@en
Targeted therapy in pediatric and adolescent oncology.
@nl
P2860
P356
P1433
P1476
Targeted therapy in pediatric and adolescent oncology.
@en
P2093
Mark L Bernstein
P2860
P304
P356
10.1002/CNCR.26050
P407
P433
P577
2011-05-01T00:00:00Z